Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareOregon Onureg prior auth Coverage Update | Ope…
    Ask Trek AI about this page
    CurrentcareoregonPolicy N/A

    Onureg (azacitidine - oral) prior authorization

    Customize your policy alerts

    Sign up for all careoregon policy alerts

    Know when careoregon releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization requirements and coverage criteria for Onureg (oral azacitidine) for CareOregon members, including initial and reauthorization criteria and required prescriber specialty. Affects providers requesting coverage for Onureg.

    Policy Summary
    Payercareoregon
    PolicyOnureg (azacitidine - oral) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing prescriber is a hematologist/oncologist and that use is supported by NCCN guidelines or FDA approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsstandard approval length
    7/1/2026effective date
    hematologist/oncologistprescriber restriction
    NCCN or FDAclinical support required

    Coverage Criteria for Onureg (oral azacitidine)

    Policy Summary
    Payercareoregon
    PolicyOnureg (azacitidine - oral) prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing prescriber is a hematologist/oncologist and that use is supported by NCCN guidelines or FDA approval.
    SourceLink
    On This Page
    Coverage Criteria for Onureg (oral azacitidine)Initial TherapyContinuation / Reauthorization CriteriaProvider Actions and Documentation RequirementsStep Therapy / Prior Agent RequirementsKey DefinitionsBackground

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    inv-01: Initial Authorization

    Covered when ALL of the following are met:

    Initial Authorization: Prescribed by or in consultation with a hematologist or oncologist.
    Guideline support: Requested drug is supported for the patient’s diagnosis in the NCCN guidelines.

    If not supported, request will be forwarded for external specialty review.

    FDA approval: Requested drug is FDA-approved for the condition being treated.

    If not FDA-approved for the condition, external specialty review is required.

    inv-02: Reauthorization

    Covered on reauthorization when ALL of the following are met:

    No progressive disease: Patient does not show evidence of progressive disease.
    Parenteral contraindication (when applicable): Patient has a contraindication to parenteral hypomethylating agents such as IV/SQ azacitidine or IV decitabine.

    This policy does not list any additional explicit coverage exclusions beyond the core requirements already specified. Coverage is conditioned on prescriber specialty (must be prescribed by or in consultation with a hematologist or oncologist) and that the use is supported by NCCN guidelines or is FDA‑approved for the patient’s diagnosis; no other specific criteria or exclusions are specified in the document.

    Requests that do not meet the guideline/FDA support or prescriber specialty requirements may be escalated for external specialty review or denied per the policy language.

    Initial Therapy

    inv-12: Initial Therapy criteria (detailed criteria for starting therapy)

    Initial authorization criteria

    Initial: Prescribed by or in consultation with a hematologist or oncologist; requested drug is supported for the patient’s diagnosis in the NCCN guidelines; requested drug is FDA-approved for the condition being treated.

    Approval length: 12 months.

    Continuation / Reauthorization Criteria

    inv-13: Reauthorization criteria for continuation of therapy

    Reauthorization criteria

    Continuation: Patient does not show evidence of progressive disease.

    Approval length is 12 months.

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior authorization required — initial approvals 12 months

    Prior authorization is required for Onureg; initial approvals are issued for 12 months. Requests must meet the policy's specialty and evidence requirements (prescribed by or in consultation with a hematologist/oncologist, supported by NCCN guidelines, and FDA-approved for the condition) and applicable contraindication criteria.

    Step Therapy

    Parenteral agent contraindication allowed for coverage

    Coverage may be considered when the patient has a documented contraindication to parenteral hypomethylating agents such as azacitidine IV/SQ or decitabine IV.

    Documentation Required

    Required documentation — prescriber specialty and evidence support

    Include documentation that the prescriber is a hematologist or oncologist or that the prescriber consulted with a hematologist/oncologist, and documentation that the requested use is supported by NCCN guidelines or is FDA‑approved for the condition.

    Documentation Required

    Reauthorization documentation — absence of progressive disease

    For reauthorization requests, provide documentation that the patient does not show evidence of progressive disease to support continued coverage.

    Denial Risk

    Denial risk — lack of NCCN guideline or FDA support

    Requests may be denied if the requested drug is not supported for the patient's diagnosis in the NCCN guidelines or is not FDA‑approved for the condition being treated; such cases will be forwarded for external specialty review.

    Denial Risk

    Denial risk — prescriber specialty requirement

    Requests may be denied if the drug is not prescribed by, or in consultation with, a hematologist or oncologist.

    Step Therapy / Prior Agent Requirements

    StepRequirementCoverage
    {"text":"1","status":""},{"text":"Patient has a contraindication to parenteral hypomethylating agents (e.g., IV/SQ azacitidine or IV decitabine).","status":""},{"text":"Coverage considered on reauthorization when criterion met; approval length 12 months.","status":"covered_with_criteria"}

    Key Definitions

    Prescriber requirement
    RequirementMust be prescribed by or in consultation with a hematologist or oncologist.
    Documentation neededProvider must document that the prescriber is a hematologist or oncologist or that consultation occurred.
    EnforcementRequests may be denied if not prescribed by or in consultation with a hematologist or oncologist.
    Applies toInitial authorization and reauthorization requests for Onureg (oral azacitidine).

    Background

    Onureg (oral azacitidine) is governed in this policy as an oral hypomethylating agent whose coverage is aligned with specialty practice: the drug must be prescribed by or in consultation with a hematologist or oncologist. In addition, coverage requires that the requested use be supported by NCCN guidelines or be FDA‑approved for the treated condition; if these supports are absent the request is subject to external specialty review.

    Reauthorization and continuation considerations are tied to the same specialty and evidence requirements outlined above, and the policy provides a pathway for coverage decisions when parenteral hypomethylating agents are not appropriate (see step‑therapy/contraindication guidance).